• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Scott Berry

2019-04-24News

What is your current role in EPAD?

I am a co-lead of Work Package 2 – The Statistical Engine Room.  The Statistical Work Package has two main focuses in the EPAD project – the design of the proof-of-concept platform trial and the disease modeling work from the Longitudinal Cohort Study (LCS).  I have been focused on working with the EPAD team to create a platform trial design for the phase 2 proof-of-concept trial (PoC). This will allow multiple therapies to be investigated simultaneously in the same protocol creating a great deal of synergy – for example sharing controls across arms.

What did you do prior to joining EPAD?

I am a PhD Statistician and President at Berry Consultants, a statistical consulting company specializing in designing adaptive and innovative trial designs, typically from a Bayesian perspective.  We work for a wide range of sponsors – large and small pharma, device companies, federally funded trials, and NGO based efforts.  We work on designing flexible adaptive trials.  This process involves creating the modeling and adaptive features of a design.  Typically, this involves detailed clinical trial simulations in order to optimize the design – making sure that the adaptive features, modeling and threshold are all optimized for the goals of the trial.  The design of adaptive trials is a very detailed process of iterative trial design aspects tied to detailed clinical trial simulations.  Traditional, fixed, trials can be understood with pencil-and-paper calculations, but more complex trial designs are simulated to understand their behavior – much like the simulation design of airplanes, automobiles, and bridges – well almost everything nowadays.  Trials constructed through simulations have been given the moniker of “complex” innovative trials.  This has been the space of trial designs we have been working on. 

Recently platform trials have been gaining in popularity.  The I-Spy2 trial was one of the first platform trails (with more than 14 different experimental agents moving through the phase 2 trial) and its popularity and growing need for more efficient methods have led to this growth and demand for platform trials.  Platform trials are being constructed in multiple cancers, ALS, Duchenne muscular dystrophy, various infectious diseases, PTSD, as well as familial Alzheimer’s.  These trials typically fall in this bucket of complex trial designs.   

Tell us a bit about the institution/company/organisation you work for.

Berry Consultants has offices in the UK and the United States, and we focus on statistical innovation – typically tied to the design and analysis of innovative trial designs.  Berry Consultants is approaching its 20th year – after being founded in 2000 by Don Berry and myself.  We have since grown to more than 30 employees – experts in statistics, clinical trials, and clinical trial simulation.  In addition to the design of trials, Berry Consultants has created and continues to develop a software package for clinical trial simulations, for the evaluation and optimization of trial designs (Fixed and Adaptive Clinical Trial Simulator, FACTS). 

What are your expectations from the EPAD project?

I have incredibly high hopes for EPAD.  I believe the PoC trial that comes out of the EPAD project will continue perpetually as long as there is a need in the slowing and prevention of Alzheimer’s disease.  The project is unique in the construction of the LCS feeding to the PoC trial.  I believe the PoC trial will prove to be an incredibly efficient ‘machine’ for phase 2 Alzheimer’s drugs – which will decrease costs, improve timelines, and ultimately improve the industries ability to investigate experimental drugs.  Not only will this have substantial impact on Alzheimer’s disease but the project itself will likely become a model project that can be emulated in many other diseases. 

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
2021-04-06
AD Workbench
The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
2021-03-18
EPAD_WordCloud
EPAD releases its first data and sample access bulletin
2021-03-10
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Latest News
  • New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
    2021-04-06
  • AD Workbench
    The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
    2021-03-18
  • EPAD_WordCloud
    EPAD releases its first data and sample access bulletin
    2021-03-10
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

If you're attending #BNA2021, check out the pre-registration poster from @GregorySarah introducing the SPeAk study. Participants of this new study must have previously enrolled in the @IMI_EPAD LCS or CHARIOT Pro study at @CenDemPrevent. #biomarker #Alzheimer’s disease #dementia twitter.com/CenDemPrevent/…

reply retweet favorite
10:18 am · 2021-04-14
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the last @IMI_EPAD publication on the application of the #ATN classification scheme in the first 1500 participants consented in the EPAD Longitudinal Cohort Study. ep-ad.org/2021/04/06/new… @silvia_ingala @IMI_JU @EFPIA @EU_H2020 pic.twitter.com/3HhgMcBDN0

reply retweet favorite
8:15 am · 2021-04-13
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Bioresource consists of over 100,000 samples consisting of blood, CSF, saliva and urine that have been collected annually from research participants throughout their participation in the Longitudinal Cohort Study. #OpenAccess ep-ad.org/2021/03/10/epa… twitter.com/IMI_EPAD/statu… pic.twitter.com/dRjuI1opFi

reply retweet favorite
7:16 am · 2021-04-12
Twitter
EPAD
EPAD
@IMI_EPAD

The ATN classification has been added for public use to the analytical database of the @IMI_EPAD Longitudinal Cohort Study, hosted by @aridhia . ⬇️ ep-ad.org/2021/04/06/new… twitter.com/IMI_EPAD/statu…

reply retweet favorite
5:56 am · 2021-04-07
Twitter
EPAD
EPAD
@IMI_EPAD

In this article, the #ATN classification was operationalized in the first 1500 participants consented in the @IMI_EPAD cohort, a deeply phenotyped cohort of individuals who do not have #dementia. ep-ad.org/2021/04/06/new…

reply retweet favorite
7:08 am · 2021-04-06
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.